Table 1.
Current breast cancer immunotherapy trials
| Therapy | Condition | Trial | Trial ID | Phase |
|---|---|---|---|---|
| DC | Stage II and III | Chemotherapy followed by Autologous DC and surgery with/without radiation and/or hormone Therapy | NCT00499083 | II |
| Locally recurrent or metastatic | Vaccine therapy, trastuzumab, and vinorelbine | NCT00266110 | II | |
| TNBC and ER+/HER2- | Safety trial for chemotherapy and DC vaccine | NCT02018458 | I, II | |
| P53 overexpression and Stage III | Vaccine therapy + adjuvant/neoadjuvant chemotherapy + adjuvant radiation therapy | NCT00082641 | I, II | |
| Metastatic BC | Vaccine therapy + 1-MT | NCT01042535 | I, II | |
| Stage IV | DC/tumor fusion + IL12 | NCT00622401 | I, II | |
| HER-2 driven invasive breast cancer at least Stage IIIA | HER-2 pulsed Dendritic Cell Vaccine | NCT02063724 | I | |
| Locally recurrent/metastatic BC | Vaccine therapy + with trastuzumab + vinorelbine | NCT00088985 | II | |
| Adoptive T-cell therapy | Stage IV | Ex vivo-expanded HER2-specific T cells | NCT00791037 | I, II |
| Anti-PD-1/PD-L1 | Advanced, trastuzumab-resistant, HER2+ BC | Ant-PD-1 (Pembrolizumab; MK-3475) | NCT02129556 | I, II |
| Metastatic TNBC | Pembrolizumab + radiotherapy | NCT02730130 | II | |
| TNBC | Pembrolizumab (MK-3475) + chemotherapy as neoadjuvant treatment | NCT02622074 | I | |
| Advanced/metastatic TNBC and OC | Niraparib + pembrolizumab | NCT02657889 | I, II | |
| HER2 overexpressing metastatic BC | Pembrolizumab + monoclonal antibody therapy | NCT02318901 | ||
| TNBC | Pembrolizumab + epacadostat | NCT02178722 | I, II | |
| Trastuzumab emtansine + atezolizumab/atezolizumab-placebo | NCT02924883 | II | ||
| Metastatic TNBC | Cobimetinib (MEK inhibitor) + paclitaxel, Cobimetinib + atezolizumab Plus Paclitaxel, or Cobimetinib + atezolizumab + Nab-Paclitaxel | NCT02322814 | II | |
| Relapsed/refractory BC | Ibrutinib + durvalumab (MEDI4736) | NCT02403271 | I, II | |
| Stage IV HER2- BC | Ipilimumab and Nivolumab | NCT02892734 | II | |
| Metastatic TNBC | SYK inhibitor (TAK-659) + nivolumab | NCT02834247 | I | |
| TNBC | Anti-PDL1 (MEDI4736) monotherapy or MEDI4736 + tremelimumab (anti-CTLA4) | NCT02527434 | II | |
| Anti-CTLA4 | Recurrent Stage IV HER2- BC | Ipilimumab and Nivolumab | NCT02892734 | II |
BC: Breast cancer; 1MT: 1-methyl-d-tryptophan; OC: Ovarian cancer; TNBC: triple-negative breast cancer; HER2: Human epidermal growth factor receptor 2; ER: estrogen receptor, IL: interleukin.